DELCATH SYSTEMS INC (DCTH) Stock Fundamental Analysis
USA - NASDAQ:DCTH - US24661P8077 - Common Stock
11.1 USD
+0.45 (+4.23%)
11.3 USD
+0.2 (+1.8%)
DCTH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. While DCTH has a great health rating, its profitability is only average at the moment. DCTH is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
DCTH had positive earnings in the past year.
In the past year DCTH had a positive cash flow from operations.
In the past 5 years DCTH always reported negative net income.
In the past 5 years DCTH always reported negative operating cash flow.
1.2 Ratios
DCTH's Return On Assets of 1.91% is fine compared to the rest of the industry. DCTH outperforms 74.87% of its industry peers.
The Return On Equity of DCTH (2.13%) is better than 75.39% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.72%, DCTH is in the better half of the industry, outperforming 72.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.91% | ||
| ROE | 2.13% | ||
| ROIC | 3.72% |
ROA(3y)-120.78%
ROA(5y)-101.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 3.18%, DCTH is in the better half of the industry, outperforming 74.87% of the companies in the same industry.
With a decent Operating Margin value of 7.14%, DCTH is doing good in the industry, outperforming 75.39% of the companies in the same industry.
DCTH has a better Gross Margin (85.86%) than 96.34% of its industry peers.
In the last couple of years the Gross Margin of DCTH has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.14% | ||
| PM (TTM) | 3.18% | ||
| GM | 85.86% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.01%
GM growth 5Y8.9%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DCTH is destroying value.
The number of shares outstanding for DCTH has been increased compared to 1 year ago.
DCTH has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DCTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
DCTH has an Altman-Z score of 15.07. This indicates that DCTH is financially healthy and has little risk of bankruptcy at the moment.
DCTH has a Altman-Z score of 15.07. This is amongst the best in the industry. DCTH outperforms 93.72% of its industry peers.
There is no outstanding debt for DCTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.07 |
ROIC/WACC0.42
WACC8.91%
2.3 Liquidity
DCTH has a Current Ratio of 10.88. This indicates that DCTH is financially healthy and has no problem in meeting its short term obligations.
DCTH has a better Current ratio (10.88) than 94.76% of its industry peers.
DCTH has a Quick Ratio of 9.87. This indicates that DCTH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.87, DCTH belongs to the top of the industry, outperforming 93.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.88 | ||
| Quick Ratio | 9.87 |
3. Growth
3.1 Past
DCTH shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 101.96%, which is quite impressive.
DCTH shows a strong growth in Revenue. In the last year, the Revenue has grown by 491.54%.
The Revenue has been growing by 88.10% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)101.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.58%
Revenue 1Y (TTM)491.54%
Revenue growth 3Y118.63%
Revenue growth 5Y88.1%
Sales Q2Q%211.05%
3.2 Future
DCTH is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.35% yearly.
The Revenue is expected to grow by 44.35% on average over the next years. This is a very strong growth
EPS Next Y104.91%
EPS Next 2Y58.76%
EPS Next 3Y45.04%
EPS Next 5Y31.35%
Revenue Next Year163.5%
Revenue Next 2Y93.97%
Revenue Next 3Y67.12%
Revenue Next 5Y44.35%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
DCTH is valuated quite expensively with a Price/Earnings ratio of 222.00.
Based on the Price/Earnings ratio, DCTH is valued a bit cheaper than the industry average as 64.92% of the companies are valued more expensively.
DCTH's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.86.
A Price/Forward Earnings ratio of 21.76 indicates a rather expensive valuation of DCTH.
DCTH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. DCTH is cheaper than 78.53% of the companies in the same industry.
DCTH's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.32.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 222 | ||
| Fwd PE | 21.76 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DCTH indicates a somewhat cheap valuation: DCTH is cheaper than 66.49% of the companies listed in the same industry.
DCTH's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. DCTH is cheaper than 69.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 100.41 | ||
| EV/EBITDA | 50.35 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
DCTH's earnings are expected to grow with 45.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.12
PEG (5Y)N/A
EPS Next 2Y58.76%
EPS Next 3Y45.04%
5. Dividend
5.1 Amount
No dividends for DCTH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
11.1
+0.45 (+4.23%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners52.77%
Inst Owner Change0%
Ins Owners2.72%
Ins Owner Change1.29%
Market Cap388.28M
Analysts84.62
Price Target25.21 (127.12%)
Short Float %9.39%
Short Ratio4.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)135.29%
Min EPS beat(2)96.08%
Max EPS beat(2)174.51%
EPS beat(4)3
Avg EPS beat(4)-22.09%
Min EPS beat(4)-488.34%
Max EPS beat(4)174.51%
EPS beat(8)5
Avg EPS beat(8)-27.41%
EPS beat(12)6
Avg EPS beat(12)-22.87%
EPS beat(16)8
Avg EPS beat(16)-16.26%
Revenue beat(2)2
Avg Revenue beat(2)9.49%
Min Revenue beat(2)3.72%
Max Revenue beat(2)15.26%
Revenue beat(4)4
Avg Revenue beat(4)7.85%
Min Revenue beat(4)3.72%
Max Revenue beat(4)15.26%
Revenue beat(8)6
Avg Revenue beat(8)9.82%
Revenue beat(12)7
Avg Revenue beat(12)1.26%
Revenue beat(16)11
Avg Revenue beat(16)26.75%
PT rev (1m)0%
PT rev (3m)2.98%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-222.46%
EPS NY rev (1m)650.06%
EPS NY rev (3m)-67.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.95%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 222 | ||
| Fwd PE | 21.76 | ||
| P/S | 5.53 | ||
| P/FCF | 100.41 | ||
| P/OCF | 80.06 | ||
| P/B | 3.7 | ||
| P/tB | 3.7 | ||
| EV/EBITDA | 50.35 |
EPS(TTM)0.05
EY0.45%
EPS(NY)0.51
Fwd EY4.59%
FCF(TTM)0.11
FCFY1%
OCF(TTM)0.14
OCFY1.25%
SpS2.01
BVpS3
TBVpS3
PEG (NY)2.12
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.91% | ||
| ROE | 2.13% | ||
| ROCE | 4.71% | ||
| ROIC | 3.72% | ||
| ROICexc | 15.57% | ||
| ROICexgc | 15.57% | ||
| OM | 7.14% | ||
| PM (TTM) | 3.18% | ||
| GM | 85.86% | ||
| FCFM | 5.51% |
ROA(3y)-120.78%
ROA(5y)-101.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.01%
GM growth 5Y8.9%
F-Score8
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 592.17% | ||
| Cap/Sales | 1.4% | ||
| Interest Coverage | 5.82 | ||
| Cash Conversion | 93.67% | ||
| Profit Quality | 173.25% | ||
| Current Ratio | 10.88 | ||
| Quick Ratio | 9.87 | ||
| Altman-Z | 15.07 |
F-Score8
WACC8.91%
ROIC/WACC0.42
Cap/Depr(3y)208.01%
Cap/Depr(5y)235.23%
Cap/Sales(3y)4.01%
Cap/Sales(5y)12.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)101.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.58%
EPS Next Y104.91%
EPS Next 2Y58.76%
EPS Next 3Y45.04%
EPS Next 5Y31.35%
Revenue 1Y (TTM)491.54%
Revenue growth 3Y118.63%
Revenue growth 5Y88.1%
Sales Q2Q%211.05%
Revenue Next Year163.5%
Revenue Next 2Y93.97%
Revenue Next 3Y67.12%
Revenue Next 5Y44.35%
EBIT growth 1Y113.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year244.81%
EBIT Next 3Y81.25%
EBIT Next 5YN/A
FCF growth 1Y114.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y118.34%
OCF growth 3YN/A
OCF growth 5YN/A